Biology subjects

Ahmad, M. N.

Publications and source records attributed to Ahmad, M. N..

3 recordsLinked to original sources

bioRxiv2026

Extraction-dependent bone proteomics reveals distinct stable and dynamic protein modules during early post-exposure degradation

Bone is a highly durable biological tissue widely used in forensic, archaeological, and anthropological investigations; however, efficient protein recovery and understanding of protein stability over time remain major challenges in skeletal proteomics. Here, we systematically evaluated three bone protein extraction workflows and integrated them with data-independent acquisition (DIA) mass spectrometry to assess proteome coverage, reproducibility, and temporal protein dynamics under environmentally exposed conditions. Comparative analysis demonstrated that extraction strategy is a primary determinant of detectable proteome composition. EDTA-based demineralization followed by SDS extraction provided the deepest proteome coverage and highest reproducibility, whereas guanidine hydrochloride extraction preferentially enriched collagen and extracellular matrix proteins. In contrast, acid-based extraction yielded limited protein recovery. Temporal profiling of bone samples collected at 10 and 45 days post-exposure revealed two distinct protein classes. A temporally stable module, enriched in collagens and extracellular matrix proteins including COL1A2, COL5A2, BGN, SPARCL1, and NID2, exhibited minimal abundance change, indicating resistance to environmental degradation. In contrast, temporally dynamic proteins, enriched in mitochondrial, metabolic, and intracellular pathways such as ACO2, OGDH, PDHA1, ATP5PO, and PFKM, showed marked decline over time. These findings support a two-compartment model of bone protein preservation in which matrix-embedded proteins are preferentially retained while exposed intracellular proteins undergo progressive degradation. Collectively, this study establishes an integrated framework linking extraction methodology with temporal proteome stability and identifies candidate markers for skeletal preservation assessment and temporal biomarker development in forensic and archaeological applications.

systems biology↗

bioRxiv2025

In vitro and in vivo synergy of Vancomycin and β-lactams against drug-resistant Mycobacterium tuberculosis and Non-tuberculous mycobacteria

The unabated increase in antimicrobial resistance has underlined the importance of identifying novel drug combinations which eliminate infections more potently and likely reduce the emergence of resistance. In this context, we have identified Vancomycin and many {beta}-lactams as being potently active against drug-resistant Mycobacterium tuberculosis and non-tuberculous mycobacteria including M. abscessus, emerging as pathogens of concern owing to their inherent drug resistance profile. In this study, we have identified combinations of Vancomycin, a glycopeptide and {beta}-lactams, especially Ceftriaxone, Ceftazidime and Meropenem, in the presence or absence of Sulbactam, a {beta}- lactamase inhibitor, as possessing potent antimicrobial activity against several drug-resistant mycobacterial strains. The combination of Vancomycin and {beta}-lactams exhibited potent bactericidal activity and reduced the bacterial load better than either drug alone. The molecular basis of synergy was mediated by increase in permeability of mycobacterial cell as demonstrated by ethidium bromide assay. In the murine model of mycobacterial infection, synergistic combination of Vancomycin and {beta}-lactams outperformed clinically utilized drugs including Isoniazid, Rifampicin and Ethambutol against M. tuberculosis and Amikacin, Clarithromycin against M. abscessus. The combinations caused a significant reduction in bacterial load in various organs in M. tuberculosis and M. abscessus infected mice. Thus, the synergistic combination of Vancomycin and {beta}-lactams could potentially be utilized for treatment of recalcitrant mycobacterial infection especially those caused due to drug-resistant pathogens.

microbiology↗

bioRxiv2022

In vitro and in vivo activity of Gepotidacin against drug-resistant mycobacterial infections

Mycobacterial pathogens including Non-tuberculous mycobacteria (NTM) and M. tuberculosis (Mtb), are pathogens of significant worldwide interest owing to inherent drug resistance to a wide variety of FDA-approved drugs as well as causing a broad range of serious infections. Identifying new antibiotics active against mycobacterial pathogens is an urgent unmet need, especially those antibiotics that can bypass existing resistance mechanisms. In this study, we demonstrate that Gepotidacin, a first-in-class triazaacenapthylene topoisomerase inhibitor, shows potent activity against Mtb and M. fortuitum as well as against other NTMs species, including fluoroquinolone-resistant M. abscessus. Furthermore, Gepotidacin exhibits concentration-dependent bactericidal activity against various mycobacterial pathogens, synergizes with several drugs utilized for their treatment, and reduces bacterial load in macrophages in the intracellular killing assay comparable to amikacin. Additionally, M. fortuitum ATCC 6841 was unable to generate resistance to Gepotidacin in vitro. When tested in a murine neutropenic M. fortuitum infection model, Gepotidacin caused a significant reduction in bacterial load in various organs at 10 fold lower concentration than amikacin. Taken together, Gepotidacin possesses a potentially new mechanism of action that enables it to escape existing resistance mechanisms. Thus, it can be projected as a potent novel lead for the treatment of mycobacterial infections, particularly for NTM, where present therapeutic interventions are very limited.

microbiology↗